By comparing SGLT2 inhibitors to DPP-4 inhibitors combined with insulin therapy for patients with T2D, a meta-analysis revealed that the former resulted in better glycemic control and lower levels of HbA1c [weighted mean difference (WMD) 0.24%, 95% CI 0.05–0.43] and FBG (WMD 18.0 mg/dl, 95% CI 7.6–28.5 mg/dl) than the latter (18). Here, DPP4 is linked to type 2 diabetes mellitus.